RABOISSON, PIERRE JEAN-MARIE BERNARD,DE KOCK, HERMAN AUGUSTINUS,VENDEVILLE, SANDRINE MARIE HELENE,HU, LILI,VAN DE VREKEN, WIM,MC GOWAN, DAVID CRAIG,TAHRI, ABDELLAH,SURLERAUX, DOMINIQUE LOUIS NESTOR GH
申请号：
CA2617095
公开号：
CA2617095C
申请日:
2006.07.28
申请国别(地区):
CA
年份:
2014
代理人:
摘要：
Inhibitors of HCV of formula (I), and the N-oxides, salts, andstereochemically isomeric forms thereof, wherein R1 is aryl or a saturated, apartially unsaturated or completely unsaturated 5 or 6 membered monocyclic or8 to 12 membered bicyclic heterocyclic ring system containing one nitrogen,and optionally one to three oxygen, sulfur or nitrogen, wherein said ringsystem may be optionally substituted； L is a direct bond, -O-. -O-C1-4alkanediyl-, -O-CO-, -O-C(=O)-NR5a- or -O-C(=O)-NR5a-C1-4alkanediyl-； R2 ishydrogen, -OR6, -C(O)OR6, -C(=O)R7, -C(=O)NR5aR5b, -C(=O)NHR5c, -NR5aR5b, -NHR5c, -NHSOpNR5aR5b, -NR5aSOpR8, or -B(OR6)2； R3 and R4 are hydrogen or C1-6alkyl； or R3 and R4 taken together may form a C3-7cycloalkyl ring； n is 3, 4,5, or 6； p is 1 or 2； aryl is phenyl, naphthyl, indanyl, or 1,2,3,4-tetrahydronaphthyl, each of which may be optionally substituted Het is a 5 or6 membered saturated, partially unsaturated or completely unsaturatedheterocyclic ring containing 1 to 4 heteroatoms each independently selectedfrom nitrogen, oxygen and sulfur, being optionally condensed with a benzenering, and wherein the group Het as a whole may be optionally substituted ；pharmaceutical compositions containing compounds (I) and processes forpreparing compounds (I). Bioavailable combinations of the inhibitors of HCV offormula (I) with ritonavir are also provided.
